Skip to main content

Advertisement

Table 3 Summary of outcomes of studies of acetylcysteine for prevention of contrast-induced nephropathy.

From: Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: A systematic review and meta-analysis

First Author Contrast-induced nephropathy* Acetylcysteine Serum Creatinine (μmol/L) Control Serum Creatinine (μmol/L) Dialysis (N)
  Acetylcysteine Control Baseline Second SCr Baseline Second SCr NAC Control
Allaqaband 25 8/45 (18%) 6/40 (15%) 194.5 196.3 179.5 179.5 2 0
Baker 26 2/41 (5%) 8/39 (21%) 163.6 156.5 154.7 159.1 0 0
Briguori 27 6/92 (7%) 10/91 (11%) 134.4 130.8 136.1 135.3 0 1
Diaz-Sandoval 28 2/25 (8%) 13/29 (45%) 146.7 135.5 137.9 166.2 0 0
Durham 29 10/38 (26%) 9/41 (22%) 194.5 NR 203.3 NR NR NR
Efrati 30 0/24 (0%) 2/25 (8%) 135.3 143.2 131.7 143.2 0 0
Fung 31 8/46 (17%) 6/45 (13%) 200.7 216.6 209.5 212.2 NR NR
Goldenberg 32 4/41 (10%) 3/39 (8%) 176.8 176.8 168.0 165.3 0 0
Kay 33 4/102 (4%) 12/98 (12%) 119.3 107.8 120.2 122.0 0 0
Kefer 34 2/53 (8%) 3/51 (6%) 91.9 91.1 102.5 93.7 0 0
MacNeill 35 1/21 (5%) 7/22 (32%) 167.1 168.0 168.0 210.4 NR NR
Oldemeyer 36 4/49 (8%) 3/47 (6%) 144.1 NR 146.7 NR 0 0
Shyu 37 2/60 (3%) 15/61 (25%) 247.5 221.0 247.5 274.0 0 1
Vallero 38 4/47 (9%) 4/53 (8%) 87.5 93.7 84 86.6 NR NR
  1. Legend: SCr = serum creatinine (for conversion to mg/dL divide by 88.4); NR = not recorded or available. *Values are numbers of patients with contrast-induced nephropathy/total number of patients in treatment group (%).